Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Open access
Remon, Jordi, Passiglia, Francesco, Ahn, Myung-Ju, Barlesi, Fabrice, Forde, Patrick M., Garon, Edward B., Gettinger, Scott, Goldberg, Sarah B., Herbst, Roy S., Horn, Leora, Kubota, Kaoru, Lu, Shun, Mezquita, Laura, Paz-Ares, Luis, Popat, Sanjay, Schalper, Kurt A., Skoulidis, Ferdinandos, Reck, Martin, Adjei, Alex A., Scagliotti, Giorgio V. · 2020 · Journal of Thoracic Oncology

Abstract

In the last 10 years a deeper understanding of the immune landscape of cancers, including immune-evasion processes, has allowed the development of a new class of agents. The re-activation of host anti-tumor immune response, offers the potential for long-term survival benefit in a portion of patients with thoracic malignancies. The advent of programmed death-1 (PD-1) / programmed death ligand-1 (PD-L1) immune-checkpoint inhibitors (ICI), both as single agents and in combination with chemotherapy, and more recently combination of ICI, anti-PD1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, have led to breakthrough therapeutic advances for patients with advanced non-small cell lung cancer (NSCLC) and to a lesser extent, patients with small cell lung cancer (SCLC). Encouraging activity has recently emerged in pre-treated patients with thymic carcinoma. Conversely in malignant pleural mesothelioma, pivotal positive signs of activity have not been fully confirmed in randomized trials. The additive effects of chemoradiation and immunotherapy suggested intriguing potential for therapeutic synergy with combination strategies. This has led to the introduction of ICI consolidation therapy in stage III NSCLC creating a platform for future therapeutic developments in earlier stage disease. Despite the definitive clinical benefit observed with ICI, primary and acquired resistance represent well-known biological phenomena, which may significantly impact the therapeutic efficacy of these agents. The development of innovative strategies to overcome ICI resistance, standardization of new patterns of ICI progression, identification of predictive biomarkers of response, optimal treatment duration, and characterization of ICI efficacy in special populations, represent crucial issues to be adequately addressed, with the aim of improving the therapeutic benefit of ICI in patients with thoracic malignancies. In the current paper, an international panel of experts in the field of thoracic malignancies discussed these topics, evaluating currently available scientific evidence, with the final aim of providing clinical recommendations, which may guide oncologists in their current practice, and elucidate future treatment strategies and research priorities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.03.006

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 169

Metadata

Authors
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., Kubota, K., Lu, S., Mezquita, L., Paz-Ares, L., Popat, S., Schalper, K. A., Skoulidis, F., Reck, M., Adjei, A. A., & Scagliotti, G. V.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-06
Volume
15
Issue
6
Pages
914-947
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3010741030
Cited by
169
References
70
FWCI
10.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. https://app.cochat.ai/papers/10.1016/j.jtho.2020.03.006
The paper
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., Kubota, K., Lu, S., Mezquita, L., Paz-Ares, L., Popat, S., Schalper, K. A., Skoulidis, F., Reck, M., Adjei, A. A., & Scagliotti, G. V. (2020). Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.03.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.